May 29, 2025 06:58 AM EDTUpdated 11:02 AM

PepGen ditches Duchenne programs after mid-stage fail, switches to previously halted muscle wasting therapy

Elizabeth Cairns

Senior biopharma journalist

PepGen is abandoning its exon 51-skipping Duchenne muscular dystrophy candidate after it failed a Phase 2 trial. And it is getting out of the disease …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

PepGen ditches Duchenne programs after mid-stage fail, switches to previously halted muscle wasting therapy

Elizabeth Cairns

Senior biopharma journalist

Sign up to read this article for free.

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Large pharma companies spell out reasons why tariffs will harm US investments

Supreme Court to keep mulling state PBM dispute as US urges justices to decline case

Merck, Daiichi Sankyo scrap FDA application for HER3 ADC after survival miss

DNA giant Illumina spawned an ecosystem of competitors and customers

FDA rejects Stealth's rare disease drug, but offers potential for accelerated approval

From weeks to days: how Aizon Intelligent Agents transform pharma validation

Pep­Gen ditch­es Duchenne pro­grams af­ter mid-stage fail, switch­es to pre­vi­ous­ly halt­ed mus­cle wast­ing ther­a­py

Senior biopharma journalist

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

PepGen ditches Duchenne programs after mid-stage fail, switches to previously halted muscle wasting therapy